Abstract
The protective activity of pyridoxol L,2-pyrrolidon-5 carboxylate (metadoxine) was investigated in a rat model of carbon tetrachloride (CCL4)-induced hepatic fibrosis. After 6 weeks of CCl4 treatment, the animals developed fibrosis and inflammation of the liver while those treated with CCl4+metadoxine had less severe lesions (P <0.05). Since in liver fibroplasia there are quantitative changes of the extracellular matrix components and almost invariably a decrease in albumin synthesis, we have also investigated by Northern blot analysis the expression of the cellular fibronectin, pro-alpha2(I)collagen and albumin genes. There were striking increases in fibronectin and pro-alpha2(I)collagen mRNA contents in the livers of CCL4-treated animals and these enhancements were less evident in the metadoxine-treated rats. In contrast, albumin mRNA levels, almost identical in control and metadoxine-treated rats, were lower in the CCl4-treated animals. These data suggest that metadoxine might slow the development of CCl4-mediated liver fibrosis.
| Original language | English |
|---|---|
| Pages (from-to) | 301-304 |
| Number of pages | 4 |
| Journal | Pharmacology and Toxicology |
| Volume | 73 |
| Issue number | 6 |
| Publication status | Published - 1993 |
Fingerprint
ASJC Scopus subject areas
- Health, Toxicology and Mutagenesis
- Pharmacology
- Toxicology
Cite this
Changes in expression of the albumin, fibronectin and type I procollagen genes in CCl4-induced liver fibrosis : Effect of pyridoxol L,2-pyrrolidon-5 carboxylate. / Arosio, B.; Santambrogio, D.; Galgiano, N.; Annoni, G.
In: Pharmacology and Toxicology, Vol. 73, No. 6, 1993, p. 301-304.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Changes in expression of the albumin, fibronectin and type I procollagen genes in CCl4-induced liver fibrosis
T2 - Effect of pyridoxol L,2-pyrrolidon-5 carboxylate
AU - Arosio, B.
AU - Santambrogio, D.
AU - Galgiano, N.
AU - Annoni, G.
PY - 1993
Y1 - 1993
N2 - The protective activity of pyridoxol L,2-pyrrolidon-5 carboxylate (metadoxine) was investigated in a rat model of carbon tetrachloride (CCL4)-induced hepatic fibrosis. After 6 weeks of CCl4 treatment, the animals developed fibrosis and inflammation of the liver while those treated with CCl4+metadoxine had less severe lesions (P <0.05). Since in liver fibroplasia there are quantitative changes of the extracellular matrix components and almost invariably a decrease in albumin synthesis, we have also investigated by Northern blot analysis the expression of the cellular fibronectin, pro-alpha2(I)collagen and albumin genes. There were striking increases in fibronectin and pro-alpha2(I)collagen mRNA contents in the livers of CCL4-treated animals and these enhancements were less evident in the metadoxine-treated rats. In contrast, albumin mRNA levels, almost identical in control and metadoxine-treated rats, were lower in the CCl4-treated animals. These data suggest that metadoxine might slow the development of CCl4-mediated liver fibrosis.
AB - The protective activity of pyridoxol L,2-pyrrolidon-5 carboxylate (metadoxine) was investigated in a rat model of carbon tetrachloride (CCL4)-induced hepatic fibrosis. After 6 weeks of CCl4 treatment, the animals developed fibrosis and inflammation of the liver while those treated with CCl4+metadoxine had less severe lesions (P <0.05). Since in liver fibroplasia there are quantitative changes of the extracellular matrix components and almost invariably a decrease in albumin synthesis, we have also investigated by Northern blot analysis the expression of the cellular fibronectin, pro-alpha2(I)collagen and albumin genes. There were striking increases in fibronectin and pro-alpha2(I)collagen mRNA contents in the livers of CCL4-treated animals and these enhancements were less evident in the metadoxine-treated rats. In contrast, albumin mRNA levels, almost identical in control and metadoxine-treated rats, were lower in the CCl4-treated animals. These data suggest that metadoxine might slow the development of CCl4-mediated liver fibrosis.
UR - http://www.scopus.com/inward/record.url?scp=0027763593&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027763593&partnerID=8YFLogxK
M3 - Article
C2 - 7512265
AN - SCOPUS:0027763593
VL - 73
SP - 301
EP - 304
JO - Pharmacology and Toxicology
JF - Pharmacology and Toxicology
SN - 0901-9928
IS - 6
ER -